EVEROLIMUS | EVEROLIMUS | ATC L01EG02 ATC L04AH02
ANTINEOPLASTIC INHIBITOR OF SERINE-THREONINE KINASE MTOR (MAMMALIAN TARGET OF RAPAMYCIN) DOWNSTREAM OF THE PI3K/AKT PATHWAY BY BINDING TO FKBP-12 ADVANCED PANCREATIC NEUROENDOCRINE TUMORS IMMUNOSUPPRESSANT PROPHYLAXIS OF ORGAN REJECTION TREATMENT OF RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX AND TREATMENT OF SUBEPENDYMAL GIANT CELL ASTROCYTOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (DRUG FOR RARE DISEASE IN EUROPE) | ORAL | VD 358 LITER PPB 74 PERCENT Cl 8.2 LITER / HOUR (EQN) HT 30 HOUR SOLUBILITY POORLY SOLUBLE IN WATER | FK506 BINDING PROTEIN-12 (FKBP-12)/MTOR COMPLEX | Peptidyl-prolyl cis-trans isomerase FKBP1A UNIPROT P62942 FKBP1A more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |